JP2020510050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510050A5 JP2020510050A5 JP2019549569A JP2019549569A JP2020510050A5 JP 2020510050 A5 JP2020510050 A5 JP 2020510050A5 JP 2019549569 A JP2019549569 A JP 2019549569A JP 2019549569 A JP2019549569 A JP 2019549569A JP 2020510050 A5 JP2020510050 A5 JP 2020510050A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- cell lymphoma
- composition according
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 7
- 230000000174 oncolytic Effects 0.000 claims 6
- 208000009889 Herpes Simplex Diseases 0.000 claims 4
- 241000700584 Simplexvirus Species 0.000 claims 4
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 4
- 229940121650 immune-checkpoint protein inhibitors Drugs 0.000 claims 4
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102100007290 CD274 Human genes 0.000 claims 2
- 101710012053 CD274 Proteins 0.000 claims 2
- 102100005310 CTLA4 Human genes 0.000 claims 2
- 101700054183 CTLA4 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102100013504 RPL17 Human genes 0.000 claims 2
- 108060007796 SPATA2 Proteins 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010017758 Gastric cancer Diseases 0.000 claims 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 1
- 208000003543 Lymphoma, T-Cell, Cutaneous Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 1
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038038 Rectal cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000112 colonic Effects 0.000 claims 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 201000005962 mycosis fungoide Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Claims (10)
- ユーイング肉腫、神経芽細胞腫、横紋筋肉腫様腫瘍、骨肉腫、横紋筋肉腫、Ｂ細胞性リンパ腫（例えば、びまん性大細胞型Ｂ細胞性リンパ腫）、非小細胞肺癌、結腸直腸癌、頭頸部扁平上皮癌、肝細胞癌、胃癌、乳がん（例えば、トリプルネガティブ乳癌）、皮膚Ｔ細胞性リンパ腫又は多発性骨髄腫を治療する方法で使用するための医薬組成物であって、腫瘍溶解性ウイルスを含む医薬組成物。
- 腫瘍溶解性ウイルスが、単純ヘルペスウイルスである、請求項１に記載の医薬組成物。
- 単純ヘルペスウイルスは、タリモジーン・ラハーパレプベックである、請求項２に記載の医薬組成物。
- 腫瘍溶解性ウイルスが、チェックポイント阻害剤と共に投与される、請求項１〜３のいずれか一項に記載の医薬組成物。
- Ｂ細胞性リンパ腫（例えば、びまん性大細胞型Ｂ細胞性リンパ腫）、結腸直腸がん、頭頸部扁平上皮癌又は乳がん（例えば、トリプルネガティブ乳癌）を治療する方法において使用するための、チェックポイント阻害剤を含む医薬組成物であって、前記チェックポイント阻害剤が、腫瘍溶解性ウイルスと共に投与される、医薬組成物。
- チェックポイント阻害剤が、ＣＴＬＡ−４、ＰＤ−１又はＰＤ−Ｌ１ブロッカーである、請求項５に記載の医薬組成物。
- Ｂ細胞性リンパ腫（例えば、びまん性大細胞型Ｂ細胞性リンパ腫）、結腸直腸がん、頭頸部扁平上皮癌又は乳がん（例えば、トリプルネガティブ乳癌）を治療するための、腫瘍溶解性ウイルス及びチェックポイント阻害剤を含む、医薬組成物。
- チェックポイント阻害剤は、ＣＴＬＡ−４、ＰＤ−１又はＰＤ−Ｌ１ブロッカーである、請求項７に記載の医薬組成物。
- 腫瘍溶解性ウイルスは、単純ヘルペスウイルスである、請求項７又は８に記載の腫瘍溶解性ウイルス。
- 単純ヘルペスウイルスは、タリモジーン・ラハーパレプベックである、請求項９に記載の医薬組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023066170A JP2023089171A (ja) | 2017-03-15 | 2023-04-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471875P | 2017-03-15 | 2017-03-15 | |
| US62/471,875 | 2017-03-15 | ||
| PCT/US2018/022442 WO2018170133A1 (en) | 2017-03-15 | 2018-03-14 | Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023066170A Division JP2023089171A (ja) | 2017-03-15 | 2023-04-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020510050A JP2020510050A (ja) | 2020-04-02 |
| JP2020510050A5 true JP2020510050A5 (ja) | 2021-04-22 |
Family
ID=61913527
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549569A Pending JP2020510050A (ja) | 2017-03-15 | 2018-03-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
| JP2023066170A Pending JP2023089171A (ja) | 2017-03-15 | 2023-04-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023066170A Pending JP2023089171A (ja) | 2017-03-15 | 2023-04-14 | がんを治療するための、腫瘍溶解性ウイルスの単独又はチェックポイント阻害剤との組み合わせでの使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200009204A1 (ja) |
| EP (1) | EP3595690A1 (ja) |
| JP (2) | JP2020510050A (ja) |
| CN (1) | CN110461346A (ja) |
| AU (2) | AU2018235944B2 (ja) |
| CA (1) | CA3056392A1 (ja) |
| MA (1) | MA51630A (ja) |
| MX (1) | MX2019010797A (ja) |
| WO (1) | WO2018170133A1 (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104704002B (zh) * | 2012-08-30 | 2022-05-10 | 安姆根有限公司 | 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法 |
| TW201912173A (zh) * | 2017-08-07 | 2019-04-01 | 美商安進公司 | 三陰性乳癌或結腸直腸癌伴隨肝轉移之治療 |
| CN116870165A (zh) * | 2018-08-17 | 2023-10-13 | 北京奥源和力生物技术有限公司 | 用于治疗癌症的组合及其治疗用途 |
| CN116802278A (zh) * | 2020-09-18 | 2023-09-22 | 成都美杰赛尔生物科技有限公司 | 溶瘤病毒与经改造的免疫细胞联合*** |
| WO2022170219A1 (en) | 2021-02-05 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
| CN113544263B (zh) * | 2021-06-03 | 2022-12-06 | 上海允英生物医药科技有限公司 | 溶瘤病毒载体及其应用 |
| TW202321458A (zh) * | 2021-09-22 | 2023-06-01 | 瑞典商生物創新國際公司 | 新穎抗體組合及其用途 |
| CN115463161A (zh) * | 2022-09-15 | 2022-12-13 | 广东天普生化医药股份有限公司 | 一种溶瘤病毒在制备治疗骨肉瘤的药物组合物中的应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US5585096A (en) | 1994-06-23 | 1996-12-17 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| US5728379A (en) | 1994-06-23 | 1998-03-17 | Georgetown University | Tumor- or cell-specific herpes simplex virus replication |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| CA2356937A1 (en) | 1998-12-31 | 2000-07-13 | Richard J. Whitley | Recombinant herpes simplex virus useful for treating neoplastic disease |
| AU2905199A (en) | 1999-03-15 | 2000-10-04 | Trustees Of The University Of Pennsylvania, The | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| US6764675B1 (en) | 1999-06-08 | 2004-07-20 | The Uab Research Foundation | Herpes simplex virus expressing foreign genes and method for treating cancers therewith |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ES2233600T5 (es) | 2000-01-21 | 2009-06-22 | Biovex Limited | Cepas de virus del herpes. |
| CN1286303A (zh) | 2000-08-17 | 2001-03-07 | 上海市农业科学院生物技术研究中心 | 抗人龋齿致病菌蛋白基因及其制备方法 |
| WO2002076216A1 (en) | 2001-03-27 | 2002-10-03 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CN101230334B (zh) | 2007-01-22 | 2011-06-01 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
| CN101230335B (zh) | 2007-01-22 | 2010-08-11 | 北京奥源和力生物技术有限公司 | 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物 |
| EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| PE20120341A1 (es) | 2008-12-09 | 2012-04-24 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| WO2011159877A2 (en) | 2010-06-18 | 2011-12-22 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| LT2753355T (lt) | 2011-09-08 | 2019-01-25 | New York University | Onkolitinis herpes simplex virusas ir jo terapinis panaudojimas |
| CN104704002B (zh) * | 2012-08-30 | 2022-05-10 | 安姆根有限公司 | 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法 |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| JP6843736B2 (ja) * | 2014-07-16 | 2021-03-17 | トランジェーヌＴｒａｎｓｇｅｎｅ | 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ |
| WO2017013421A1 (en) * | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood |
| CA3011157A1 (en) * | 2016-01-11 | 2017-07-20 | Turnstone Limited Partnership | Oncolytic virus and checkpoint inhibitor combination therapy |
| EP3426271A4 (en) * | 2016-03-10 | 2019-10-16 | Cold Genesys, Inc. | METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY |
| EP3225253A1 (en) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
-
2018
- 2018-03-14 CN CN201880017970.9A patent/CN110461346A/zh active Pending
- 2018-03-14 US US16/493,376 patent/US20200009204A1/en active Pending
- 2018-03-14 EP EP18716700.2A patent/EP3595690A1/en active Pending
- 2018-03-14 MA MA051630A patent/MA51630A/fr unknown
- 2018-03-14 AU AU2018235944A patent/AU2018235944B2/en active Active
- 2018-03-14 JP JP2019549569A patent/JP2020510050A/ja active Pending
- 2018-03-14 CA CA3056392A patent/CA3056392A1/en active Pending
- 2018-03-14 WO PCT/US2018/022442 patent/WO2018170133A1/en unknown
- 2018-03-14 MX MX2019010797A patent/MX2019010797A/es unknown
-
2023
- 2023-04-14 JP JP2023066170A patent/JP2023089171A/ja active Pending
-
2024
- 2024-04-02 AU AU2024202086A patent/AU2024202086A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510050A5 (ja) | ||
| HRP20191449T1 (hr) | Anti-b7-h1 i anti-ctla-4 protutijela za liječenje raka pluća ne-malih stanica | |
| Chiappinelli et al. | Combining epigenetic and immunotherapy to combat cancer | |
| JP2018516911A5 (ja) | ||
| JP2018522858A5 (ja) | ||
| JP2021102627A5 (ja) | ||
| IL278423B1 (en) | Fidi-1 / Fidi-AL1 inhibitors for cancer treatment | |
| CY1124437T1 (el) | Ανθρωπινα αντισωματα κατα toy pd-l1 | |
| MX2016008362A (es) | Combinaciones farmaceuticas. | |
| CA3018932C (en) | Pharmaceutical combinations for the treatment of cancer | |
| GEP20217282B (en) | β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT | |
| JP2019506427A5 (ja) | ||
| CY1125163T1 (el) | 2΄-υποκατεστημενα-ν6-υποκατεστημενα πουρινο νουκλεοτιδια για την θεραπεια ιων rna | |
| CY1118774T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης | |
| MY188734A (en) | Use of alphavirus in preparation of antitumor drugs | |
| PL3759083T3 (pl) | Pochodne 2,4-diaminochinazoliny i ich zastosowanie w leczeniu zakażeń wirusowych, nowotworu lub alergii | |
| RU2018127640A (ru) | Комбинация ингибитора hdac и антитела против pd-l1 для лечения рака яичников | |
| JP2016128507A5 (ja) | ||
| EA201691385A1 (ru) | Комбинированная терапия рака | |
| AU2018314227A8 (en) | Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus | |
| WO2016014527A3 (en) | Stabilized nucleotides for medical treatment | |
| RU2018128796A (ru) | Противоопухолевое средство, содержащее иммуномодулятор и усилитель противоопухолевого эффекта | |
| BRPI0808897B8 (pt) | uso de um pó compreendendo tmc278, disperso em um copolímero de vinilpirrolidona e acetato de vinila e solução supersaturada de tmc278 | |
| JP2019533682A5 (ja) | ||
| JP2019517507A5 (ja) |